Por: The Boston Globe Business November 30, 2022
An , led to “moderately less” cognitive decline in patients with early symptoms of Alzheimer’s disease, but caused side effects in some recipients that required close monitoring, according to the full findings of a late-stage clinical trial.The results, published Tuesday evening in the New England Journal of Medicine at the same time executives from Eisai began presenting them at a scientific conference on Alzheimer’s in San Francisco,... + full article
The Advocate USA Health January 02, 2023
What is Alzheimer’s disease?German neurologist Dr. Alois Alzheimer first identified this neurological disorder in 1906 while studying the pathology of a woman he had treated for an unusual mental illness.While examining her brain after her death, Alzheimer noticed marked... + más
How To Spot The Early Signs Of Alzheimer's | Newsweek
Reimagining Alzheimer’s (Part 4): Cautious Optimism For A New Alzheimer’s Disease Treatment | Forbes
ABC7 USA Health December 01, 2022
treatment, according to new Phase 3 trial results, but the findings raise some safety concerns because of its association with certain serious adverse events.Lecanemab has become one of the first experimental dementia drugs to appear to slow the progression of cognitive... + más
Alzheimer's drug trial shown to slow cognitive decline in long fight against dementia | CNBC
CNBC USA Health November 30, 2022
Alzheimer's is the most common form of dementia, a general term for loss of memory, language, and other thinking abilitiesBrian B. Bettencourt Toronto Star Getty ImagesA trial of an experimental Alzheimer's drug has been hailed as a new era in the beleaguered fight to... + más
Experimental drug appears to slow progression of Alzheimer's disease but raises safety concerns | ABC7
The Advocate USA Health November 16, 2022
What is the Lumipulse test for Alzheimer’s disease?In May, the U.S. Food and Drug Administration permitted marketing of the Lumipulse (G B-Amyloid Ratio [1-42/1-40]) test to Fujirebio Diagnostics, Inc. of Malvern, Pennsylvania. The test, which was granted Breakthrough Device... + más
Why Isn’t There an Effective Alzheimer’s Treatment Yet? | Slate
Forbes USA Tech October 22, 2022
A person walks on a suspended rope bridge in the clouds. Extreme attraction.getty This article is the fourth installment in my series on Alzheimer’s disease. Read more about Alzheimer’s disease in , , and of the series. The pharmaceutical and biotech companies, Eisai and... + más
COVID-19 in seniors linked to increased Alzheimer’s risk, study finds | Portland Press Herald
Variety of factors play a role in the development of Alzheimer's | The Advocate
Portland Press Herald USA Health September 24, 2022
A study using the electronic health records of more than 6 million Americans over age 65 found that those who had COVID-19 ran a greater risk of receiving a new diagnosis of Alzheimer’s disease within a year. The study, led by researchers at Case Western Reserve University... + más
There's a growing dementia crisis in the veteran community: Alzheimer's Q&A | The Advocate
The Advocate USA Health September 17, 2022
Alzheimer's Q&A: Sildenafil has potential as Alzheimer's drug | The Advocate
About iurex | Privacy Policy | Disclaimer |